Inozyme Pharma, Inc. (INZY)
NASDAQ$0.8675-0.06 (-6.48%)
Market Cap
$59.51M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
642 of 915
Rank in Industry
367 of 522
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
INZY Insider Trading Activity
INZY Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is …
Insider Activity of Inozyme Pharma, Inc.
Over the last 12 months, insiders at Inozyme Pharma, Inc. have bought $0 and sold $0 worth of Inozyme Pharma, Inc. stock.
On average, over the past 5 years, insiders at Inozyme Pharma, Inc. have bought $48.08M and sold $2.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 833,333 shares for transaction amount of $4M was made by Pivotal bioVenture Partners Fund I, L.P. (director) on 2023‑08‑01.
List of Insider Buy and Sell Transactions, Inozyme Pharma, Inc.
| 2024-04-02 | Sale | Treco Douglas A | CEO | 7,523 0.0122% | $6.94 | $52,210 | -35.21% | |
| 2023-08-01 | Pivotal bioVenture Partners Fund I, L.P. | director | 833,333 1.4418% | $4.80 | $4M | -7.67% | ||
| 2023-08-01 | Hopfner Robert Lorne | director | 833,333 1.4418% | $4.80 | $4M | -7.67% | ||
| 2023-05-12 | Hopfner Robert Lorne | director | 228,702 0.5377% | $6.25 | $1.43M | -20.48% | ||
| 2023-05-11 | Hopfner Robert Lorne | director | 219,230 0.5045% | $6.48 | $1.42M | -24.84% | ||
| 2023-03-29 | Hopfner Robert Lorne | director | 344,592 0.761% | $4.54 | $1.56M | +8.51% | ||
| 2023-03-28 | Hopfner Robert Lorne | director | 156,766 0.3414% | $4.16 | $652,335 | +15.79% | ||
| 2023-03-27 | Hopfner Robert Lorne | director | 51,074 0.1167% | $3.70 | $188,729 | +35.68% | ||
| 2022-12-15 | Bjarke Henric Bjorn | SVP, COO | 21,500 0.0569% | $1.39 | $29,885 | +207.91% | ||
| 2022-04-19 | ENRIGHT PATRICK G | 1.35M 2.811% | $3.69 | $5M | -33.04% | |||
| 2022-04-19 | Pivotal bioVenture Partners Fund I U.G.P., Ltd | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | |||
| 2022-04-19 | Hopfner Robert Lorne | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | |||
| 2022-04-19 | Bolte Axel | Chief Executive Officer | 67,750 0.1405% | $3.69 | $249,998 | -33.04% | ||
| 2022-04-19 | Bjarke Henric Bjorn | SVP, COO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | ||
| 2022-04-19 | Subramanian Sanjay | SVP, CFO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | ||
| 2021-06-24 | Sale | Bolte Axel | Chief Executive Officer | 66,788 <0.0001% | $0.00 | $7 | -57.67% | |
| 2021-01-28 | Sale | Novo Holdings A/S | 10 percent owner | 375,000 1.469% | $21.00 | $7.88M | -30.07% | |
| 2020-07-28 | Longitude Capital Partners III, LLC | 10 percent owner | 1.25M 6.0841% | $16.00 | $20M | +19.03% | ||
| 2020-07-28 | Novo Holdings A/S | 10 percent owner | 375,000 1.8252% | $16.00 | $6M | +19.03% | ||
| 2020-07-28 | Sonsini Peter W. | 10 percent owner | 250,000 1.2168% | $16.00 | $4M | +19.03% |
Total: 32
Insider Historical Profitability
10.15%
| ENRIGHT PATRICK G | 4174379 6.4981% | $3.87M | 1 | 0 | <0.0001% | |
| Hopfner Robert Lorne | director | 2923110 4.5503% | $2.71M | 8 | 0 | <0.0001% |
| Pivotal bioVenture Partners Fund I, L.P. | director | 2923110 4.5503% | $2.71M | 2 | 0 | +5.68% |
| Longitude Capital Partners III, LLC | 10 percent owner | 2819379 4.3888% | $2.61M | 1 | 0 | +19.03% |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | 2661154 4.1425% | $2.47M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$49,091,668 | 110 | 13.11% | $63.61M | |
$2,942,496 | 100 | 17.32% | $59.21M | |
$4,898,715 | 46 | 40.74% | $60.87M | |
$542,300 | 40 | -14.44% | $56.43M | |
$18,752,549 | 33 | -28.34% | $55.98M |
INZY Institutional Investors: Active Positions
| Increased Positions | 69 | +75.82% | 5M | +8.87% |
| Decreased Positions | 36 | -39.56% | 7M | -12.92% |
| New Positions | 35 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 4M | Sold Out |
| Total Postitions | 124 | +36.26% | 52M | -4.05% |
INZY Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Adage Capital Partners Gp, L.L.C. | $4,747.00 | 8.06% | 5.16M | -513,629 | -9.05% | 2024-12-31 |
| Pivotal Bioventure Partners Investment Advisor Llc | $4,135.00 | 7.02% | 4.49M | 0 | 0% | 2024-12-31 |
| Sofinnova Investments, Inc. | $3,938.00 | 6.69% | 4.28M | 0 | 0% | 2024-12-31 |
| Affinity Asset Advisors, Llc | $3,655.00 | 6.21% | 3.97M | +1M | +40.75% | 2024-12-31 |
| Rock Springs Capital Management Lp | $3,553.00 | 6.03% | 3.86M | +59,100 | +1.55% | 2024-12-31 |
| Blackrock, Inc. | $3,508.00 | 5.96% | 3.81M | +321,303 | +9.2% | 2024-12-31 |
| Vanguard Group Inc | $2,423.00 | 4.11% | 2.63M | +8,911 | +0.34% | 2024-12-31 |
| Nea Management Company, Llc | $2,243.00 | 3.81% | 2.44M | 0 | 0% | 2024-12-31 |
| Eventide Asset Management, Llc | $2,042.00 | 3.47% | 2.22M | -2M | -46.3% | 2024-12-31 |
| Millennium Management Llc | $1,732.00 | 2.94% | 1.88M | +137,821 | +7.9% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.